Novo Nordisk’s Wegovy pill — oral semaglutide at 25 mg, once daily — became commercially available in January 2026, following FDA approval in December 2025. It is the first oral GLP-1 receptor agonist approved specifically for weight management.

The distinction between Wegovy pill and Rybelsus matters. Rybelsus (oral semaglutide at 7 mg or 14 mg) has been available since 2019 for type 2 diabetes and received a cardiovascular risk reduction indication in October 2025. Wegovy pill is a higher-dose formulation (25 mg) with a separate approval for weight management — the same indication as injectable Wegovy.

Efficacy: in the OASIS 4 trial, oral semaglutide 25 mg produced 16.6% mean weight loss in adherent patients with obesity or overweight with at least one comorbidity. That’s substantial for an oral medication, though it trails both injectable Wegovy (~15–17% in STEP trials) and the newly approved Foundayo (orforglipron, 12.4%).

The pricing signal is significant. Novo Nordisk set the Wegovy pill at $149 per month — a deliberate move to undercut the injectable market and the compounding pharmacies that have thrived in the GLP-1 shortage era. For context, injectable Wegovy’s list price before insurance runs considerably higher.

There is a practical limitation: oral semaglutide requires taking the pill on an empty stomach with no more than 4 ounces of water, then waiting at least 30 minutes before eating, drinking, or taking other medications. Foundayo (orforglipron), approved three months later, has none of these restrictions — a convenience advantage that will likely drive competitive differentiation.

The oral GLP-1 market now has three products with two different mechanisms and different administration requirements. For patients who want efficacy without injections, the options have expanded meaningfully within a single quarter.